AU2023232991A1 - Compositions and methods for modulation of macrophage activity - Google Patents

Compositions and methods for modulation of macrophage activity Download PDF

Info

Publication number
AU2023232991A1
AU2023232991A1 AU2023232991A AU2023232991A AU2023232991A1 AU 2023232991 A1 AU2023232991 A1 AU 2023232991A1 AU 2023232991 A AU2023232991 A AU 2023232991A AU 2023232991 A AU2023232991 A AU 2023232991A AU 2023232991 A1 AU2023232991 A1 AU 2023232991A1
Authority
AU
Australia
Prior art keywords
lilrb1
human
seq
antibody
lilrb2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023232991A
Other languages
English (en)
Inventor
Luca CASSETTA
Stephen MYATT
Carola Ries
Krzysztof B. Wicher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macomics Ltd
Original Assignee
Macomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macomics Ltd filed Critical Macomics Ltd
Priority claimed from PCT/GB2023/050592 external-priority patent/WO2023170434A1/en
Publication of AU2023232991A1 publication Critical patent/AU2023232991A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2023232991A 2022-10-04 2023-03-13 Compositions and methods for modulation of macrophage activity Pending AU2023232991A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2214614.6A GB202214614D0 (en) 2022-10-04 2022-10-04 Compositions and methods for modulation of macrophage
GB2214614.6 2022-10-04
PCT/GB2023/050592 WO2023170434A1 (en) 2022-03-11 2023-03-13 Compositions and methods for modulation of macrophage activity

Publications (1)

Publication Number Publication Date
AU2023232991A1 true AU2023232991A1 (en) 2025-04-10

Family

ID=84000149

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023232991A Pending AU2023232991A1 (en) 2022-10-04 2023-03-13 Compositions and methods for modulation of macrophage activity

Country Status (8)

Country Link
JP (1) JP2025535192A (https=)
KR (1) KR20250096720A (https=)
CN (1) CN120435496A (https=)
AU (1) AU2023232991A1 (https=)
CR (1) CR20250172A (https=)
GB (1) GB202214614D0 (https=)
IL (1) IL319958A (https=)
MX (1) MX2025003929A (https=)

Also Published As

Publication number Publication date
JP2025535192A (ja) 2025-10-22
MX2025003929A (es) 2025-05-02
CR20250172A (es) 2025-09-04
IL319958A (en) 2025-05-01
CN120435496A (zh) 2025-08-05
KR20250096720A (ko) 2025-06-27
GB202214614D0 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
JP7345578B2 (ja) 新規抗ｐｄ－ｌ１抗体
US12209128B2 (en) Anti-PD-L1 antibodies
US20230192847A1 (en) Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivo
CN107530428B (zh) Icos的抗体
CN110382536B (zh) 抗pd-1抗体及其用途
US20190330351A1 (en) Anti-pd-l1 antibodies
US20160200815A1 (en) Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CN113194994B (zh) 使用抗trem2抗体的方法
US20250197491A1 (en) Compositions and methods for modulation of macrophage activity
KR20160145624A (ko) 항-ox40 항체 및 사용 방법
JP2015508757A (ja) Ｍｉｃａ結合剤
US20250171534A1 (en) Anti-lilrb1/2 antibodies and uses thereof
KR20250134230A (ko) 다중특이적 항체 및 이의 용도
CN115087672A (zh) 抗人hvem(tnfrsf14)抗体及其用途
JP2022553927A (ja) Ｉｌｔ－２阻害剤での癌の処置
CN114008077A (zh) 抗体和使用方法
CN113748132B (zh) 抗trem1抗体和相关方法
AU2023232991A1 (en) Compositions and methods for modulation of macrophage activity
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
TW202417485A (zh) 抗ｐｖｒｉｇ抗體及使用方法
EP4713370A2 (en) Antibodies and uses thereof
CN118480129A (zh) 抗体及其用途
HK40016537B (zh) 抗pd-1抗体及其用途
HK1248127B (en) Antibodies to icos